Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
1994-7-12
|
| pubmed:abstractText |
In this phase III trial, 770 patients with clinical stage I-II Hodgkin's disease (HD) have been enrolled since November 1988. Preliminary results are given for the 605 (79%) patients who have completed their initial therapy. Patients were grouped according to 6 pretreatment prognostic characteristics. In the very favourable (VF) group, treatment consisted of mantle field alone. In the favourable (F) group, patients were randomized to either subtotal nodal irradiation (STNI), or 6 cycles of EBVP (epirubicin, bleomycin, vinblastine, prednisone) followed by involved-field irradiation (IF-RT). Unfavourable (U) patients were randomized to either 6 cycles of EBVP plus IF-RT, or to 6 cycles of MOPP/ABV hybrid plus IF-RT. Of the 35 VF patients, none have progressed during radiotherapy. Four patients relapsed and were salvaged. Three-year failure-free survival (FFS) was 82%; overall survival (OS) was 100%. Of the 254 F patients, 130 were treated with STNI and 124 with EBVP plus IF-RT. At 3 years, FFS rates were 81% (1 progression, 14 relapses) and 79% (5 progressions, 8 relapses), respectively. Corresponding OS rates were 99% and 100%. Of the 316 U patients, 160 received EBVP and 156 MOPP/ABV. At 3 years, FFS rates were 72% (18 progressions, 20 relapses) and 88% (7 progressions, 6 relapses), respectively (p < 0.001). Although OS rates were identical (92%), the entry in the U-EBVP arm was stopped in November 1992. We conclude that a treatment strategy based on prognostic factors allows the use of less aggressive treatment in favourable patients.(ABSTRACT TRUNCATED AT 250 WORDS)
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Bleomycin,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Epirubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Mechlorethamine,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Procarbazine,
http://linkedlifedata.com/resource/pubmed/chemical/Vinblastine,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0923-7534
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
5 Suppl 2
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
107-12
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:7515643-Adolescent,
pubmed-meshheading:7515643-Adult,
pubmed-meshheading:7515643-Aged,
pubmed-meshheading:7515643-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:7515643-Bleomycin,
pubmed-meshheading:7515643-Combined Modality Therapy,
pubmed-meshheading:7515643-Doxorubicin,
pubmed-meshheading:7515643-Epirubicin,
pubmed-meshheading:7515643-Female,
pubmed-meshheading:7515643-Hodgkin Disease,
pubmed-meshheading:7515643-Humans,
pubmed-meshheading:7515643-Male,
pubmed-meshheading:7515643-Mechlorethamine,
pubmed-meshheading:7515643-Middle Aged,
pubmed-meshheading:7515643-Neoplasm Staging,
pubmed-meshheading:7515643-Prednisone,
pubmed-meshheading:7515643-Procarbazine,
pubmed-meshheading:7515643-Prognosis,
pubmed-meshheading:7515643-Radiotherapy,
pubmed-meshheading:7515643-Salvage Therapy,
pubmed-meshheading:7515643-Survival Rate,
pubmed-meshheading:7515643-Treatment Outcome,
pubmed-meshheading:7515643-Vinblastine,
pubmed-meshheading:7515643-Vincristine
|
| pubmed:year |
1994
|
| pubmed:articleTitle |
Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-Curie.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|